| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
|
Still deciding? Get samples of US$ 15/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Finerenone |
| CAS NO. | 1050477-31-0 |
| Specification | 99% |
| Appearance | White powder |
| packing | 1kg/bag,25kgs/drum |
| MOQ | 1KG |
Finerenone (BAY 94-8862) is a nonsteroidal selective mineralocorticoid receptor antagonist that has been shown in preclinical studies to block the deleterious effects of mineralocorticoid receptor overactivation. In patients with diabetes, mineralocorticoid receptor overactivation is thought to contribute to the progression of chronic kidney disease and cardiovascular impairment, which may be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors.
| Item | Specification | Test result |
| Appearance | white powder | Conforms |
| Assay | 99% | Conforms |
| Heavy metal | ≤10ppm | Conforms |
| Lead | ≤2.0ppm | Conforms |
| As | ≤2.0ppm | Conforms |
| Ca | ≤1.0ppm | Conforms |
| Me | ≤0.1ppm | Conforms |
| Total aerobic microbial count | ≤1000CFU/g | Conforms |
| Total moulds&yeast count | ≤100CFU/g | Conforms |
| Enterobacterial | ≤10MPN/g | Conforms |
| Salmonella | N.D/25g | Conforms |
| Escherichia coli | N.D/10g | Conforms |
| Staphylococcus aureus | N.D/10g | Conforms |
| Pseudomonas aeruginosa | N.D/10g | Conforms |
| Conclusion: Conform with specification. | ||
Once approved, Finerenone will become the first nonsteroidal selective mineralocorticoid receptor antagonist to improve renal outcomes in adults with chronic kidney disease and type 2 diabetes.
Finerenone is used in adults with chronic kidney disease associated with type 2 diabetes (estimated glomerular filtration rate [eGFR] 25 to <75 mL/min/1.73 m2, with albuminuria) to reduce the risk of sustained decline in eGFR and end-stage renal disease.
){kind=link}